MeiraGTx

MeiraGTx Q2 2025 earnings

August 14, 2025

Written by Curation

MeiraGTx Q2 2025 Earnings

Partner Agreements Updates

  • MeiraGTx will be granted an additional 250,000 Class A shares in Hologen AI, an Eric Schmidt (ex-Google CEO) venture
  • The JV provides $200M cash upfront and up to $230M more to fund the Parkinson’s program and other brain‑targeted therapies
  • MeiraGTx has received $23M of the $200M upfront payment with the remainder expected in Q3 2025

Service Revenue Up

  • Revenue came in at $3.7M, sharply higher than $0.3M in the same quarter last year.
  • Most of this came from Process Performance Qualification (PPQ) work, the formal manufacturing validation step needed before a therapy can be filed for approval, for Johnson & Johnson’s bota‑vec program for an inherited eye disease.

Reduced Quarterly Loss

  • Net loss was $38.8M versus $48.6M a year ago.
  • The improvement reflects stable costs and more income from manufacturing services, even as research and clinical trial spending continues.

Late‑Stage Trials Making Progress

  • Xerostomia (severe dry mouth) treatment in pivotal Phase 2, aiming for late‑2026 data.
  • Parkinson’s disease gene therapy received an FDA expedited review designation (RMAT); Phase 3 is planned this year.
  • Congenital blindness program preparing UK and US regulatory filings for late 2025.

Cash Outlook

  • Cash stood at $32.2M at quarter‑end compared to $103M at the end of 2024.
  • Expected milestone receipts from partners and the remainder of Hologen’s committed funding are projected to support operations into 2027, assuming clinical timelines stay on track.

All in all, this quarter highlights growing manufacturing activity, disciplined spending, and steady progress on late‑stage programs. The next major shifts will likely come from clinical results and regulatory decisions over the next two years. It will also be worth watching developments at Hologen AI, given its potential impact on MeiraGTx’s strategic trajectory.

  • Curation Connect is an information service provided by Curation Corporation. General disclaimer and copyright This weekly briefing has been commissioned by MeiraGTx and prepared and issued by Curation Connect, in consideration of a fee payable by MeiraGTx. Fees are paid upfront in cash without recourse. Curation may seek additional fees for the provision of related IR services for the client but does not get remunerated for any investment banking services. We do not take payment in stock, options or warrants for any of our services. Liability Your investments are your responsibility. No liability whatsoever is accepted by Curation Corporation Limited or any Curation Corporation company of their respective directors, officers, employees or analysts for any loss, whether direct, indirect, special, incidental or consequential, arising whether directly or indirectly as a result of the recipient acting or not acting on any information in any Curation Connect publication, including, without limitation, lost profits arising from the use of the Curation Connect service or any of its publications. We have no liability for any loss of profit, loss of revenue, loss of business, business interruption, loss of opportunity or any indirect, special or consequential loss; any losses which arise from any event beyond our reasonable control; any losses which could not reasonably have been anticipated; or your inability to access and/or use the Curation Connect service or the website. We do not exclude or limit in any way our liability to you where it would be unlawful to do so. Disclaimer Curation Connect publications are provided for general information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument or investment. This report is intended only for investors who are 'professional clients' as defined by the FCA, and may not, therefore, be redistributed to other classes of investors. This document is provided for information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument. This document does not constitute, and should not be interpreted as, investment advice. You must carry out your own independent research and obtain suitable professional advice before making any investment decision. The Curation Connect publications do not take the specific needs, investment objectives and financial situation of any particular individual into consideration and we cannot state whether any investment mentioned is suitable for you. You should not base any investment decision solely on the basis of the information we publish or provide to you. Always be aware of market risks – never invest money you cannot afford to lose. All investments can go down as well as up. Investing in securities entails risks. Potential Conflicts of Interest Curation Connect or its respective directors, officers, employees, contributors and clients may have or take positions in the securities, entities or investments mentioned in the Curation Connect publications. Any of these circumstances could create, or be perceived as creating, conflicts of interest. Privacy and Registration All information received from you and your use of the Curation Connect service and the website will be used by Curation Corporation Limited in accordance with our Privacy Policy. Please read this for details of how we may process your personal data. On registration for the Curation Connect service, you must provide us with accurate, complete registration information and it is your responsibility to update and maintain changes to your information. Curation Connect, a trading name of Curation Corporation Limited, is entitled to rely on any information you provide to us. Read our full T&Cs, disclaimers and privacy notice. Contact us at info@curationcorp.com Curation Corporation Limited, 58 Borough High Street, London, SE1 1XF, UK

Other

Articles you might like

Go to blog